SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Telix Pharmaceuticals Limited (TLPPF) , 前瞻盈利收益率 0.52%. PEG 1.73.
本页证实的标准:
- VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。
- 前瞻市盈率 192.7
- PEG 比率 1.73 — 介于1.0–2.0之间，表明相对于增长的估值适中。
SharesGrow 综合评分： 50/100 其中 2/7 项标准通过。
SharesGrow 7-Criteria Score
✗
健康
33/100
Debt-to-Equity & liquidity
→ Health
估值概览 — TLPPF
估值倍数
P/E (TTM)0.0
前瞻 P/E192.7
PEG 比率1.73
前瞻 PEG1.73
P/B 比率0.00
P/S 比率2.85
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.03
前瞻 EPS（预估）$0.05
每股账面价值$0.00
每股营收$3.69
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
Forward Earnings Yield0.52%
股息收益率0.00%
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$0.00 |
$0.00 |
$-44K |
- |
| 2017 |
$-0.05 |
$0.00 |
$-6.38M |
- |
| 2018 |
$-0.07 |
$195.14K |
$-13.83M |
-7087.1% |
| 2019 |
$-0.12 |
$3.49M |
$-27.87M |
-799.6% |
| 2020 |
$-0.17 |
$5.21M |
$-44.89M |
-861.1% |
| 2021 |
$-0.29 |
$7.6M |
$-80.51M |
-1059.9% |
| 2022 |
$-0.34 |
$160.1M |
$-104.08M |
-65% |
| 2023 |
$0.02 |
$502.55M |
$5.21M |
1% |
| 2024 |
$0.14 |
$783.21M |
$49.92M |
6.4% |
| 2025 |
$-0.03 |
$1.25B |
$-11.05M |
-0.9% |
